Company Description

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.

The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.

It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program.

The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.

BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BioVie Inc.

Country	United States
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Cuong Viet Do

Contact Details

Address: 680 W. Nye Lane, Suite 204 Carson City, Nevada 89703 United States
Phone	775 888 3162
Website	bioviepharma.com

Stock Details

Ticker Symbol	BIVIW
Exchange	NASDAQ
Stock Type	Warrants
Fiscal Year	July - June
Reporting Currency	USD

Key Executives

Name	Position
Cuong Viet Do M.B.A.	President, Chief Executive Officer and Director
Joanne Wendy Kim CPA	Chief Financial Officer, Treasurer and Corporate Secretary
Dr. Joseph M. Palumbo M.D.	Executive Vice President of Research & Development and Chief Medical Officer
Clarence N. Ahlem	Senior Vice President of Operations
Dr. Penelope Markham Ph.D.	Senior Vice President of Liver Disease Program
Denise Smith	Senior Vice President of Manufacturing and Development
Dr. Christopher L. Reading Ph.D.	Senior Vice President of Alzheimer's Disease Program